In Vivo CRO Market, By Type of Molecule (Small Molecules and Large Molecules), By Therapeutic Area (Oncology, Cardiology, Diabetes, Autoimmune/inflammation conditions, Infectious Diseases, CNS Conditions, and Others), By Service Type (Preclinical Testing,

In vivo CRO market involves contract research organizations (CROs) that help pharmaceutical and biotechnology companies in non-clinical or pre-clinical stages of drug development by outsourcing their research needs to these specialized firms. CROs conduct experiments and tests on live animals and help evaluate the efficacy, toxicity, and safety of new drug candidates. This reduces risks for drug developers and accelerates the drug approval process. Rising R&D expenditure on pharmaceuticals and medical innovations is a key driver for growth of the global in vivo CRO market. However, factors such as stringent animal welfare regulations and increasing demand for alternative testing methods pose challenges for the market.

Market Dynamics

The global in vivo CRO market is driven by rising pharmaceutical R&D expenditure, advancements in disease treatment, and growing need to reduce drug development timelines and costs. However, stringent regulations for animal testing and rising preference for alternative testing methods, such as organ-on-chip and in vitro testing, act as restraints for the market. Development of human-on-chip technology provides an opportunity for companies in this market to offer novel alternative testing solutions and align with industry shift toward non-animal methods. The COVID-19 outbreak highlighted the need for CROs to find treatments and help drug makers in pre-clinical research, thereby presenting lucrative prospects for players in this market.

Key Features of the Study:

• -This report provides in-depth analysis of the global in vivo CRO market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global in vivo CRO market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Charles River, Envigo, Taconic Biosciences, Jackson Laboratory, Crown Biosciences, Shanghai SLAC, Changle Rongshi, Pengxin Huasu and Syngene International.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global in vivo CRO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global in vivo CRO market.

• By Type of Molecule
• Small Molecules
• Large Molecules
• By Therapeutic Area
• Oncology
• Cardiology
• Diabetes
• Autoimmune/Inflammation Conditions
• Infectious Diseases
• CNS Conditions
• Others
• By Service Type
• Preclinical Testing
• Clinical Research Services
• Laboratory Services
• Consulting Services
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• IQVIA Inc.
• Crown Bioscience
• Taconic Biosciences, Inc.
• PsychoGenics Inc.
• Evotec
• Janvier Labs
• Biocytogen Boston Corp
• GemPharmatech
• Charles River Laboratories
• Icon Plc
• Labcorp Drug Development
• Parexel International Corporation
• SMO Clinical Research (I) Pvt Ltd.
• WuXi AppTec
• ICON plc
• Syneos Health